SBI MNC Fund
Direct · GrowthAI Summary
SBI MNC Fund has delivered steady SIP XIRR of 13.24% over 10Y and 13.44% over 7Y, but it trails the category average SIP XIRR across all horizons, including 16.44% over 10Y and 16.22% over 3Y. Against the NIFTY 50, the fund shows consistent lump-sum outperformance over longer periods, with 12Y CAGR of 11.26% versus the benchmark's 9.05% and a 15Y alpha of 4.45%. Recent performance is softer, with 1Y XIRR of 14.07% and a negative 3Y alpha of -1.06%.
The fund exhibits low beta of roughly 0.58-0.62 across periods, with downside capture consistently below upside capture (e.g., 62.89% upside vs 56.28% downside over 12Y), indicating strong downside resilience. Risk-adjusted returns are solid, with Calmar ratios stable around 0.50-0.61 across horizons. However, the fund has experienced 8 drawdown events exceeding 10%, and the 1Y benchmark comparison shows fund CAGR of 3.1% versus the benchmark's -12.71%, reflecting its defensive character.
The 42-stock portfolio is led by Divi's Laboratories (5.82%), Cummins India (4.77%), and Bosch (4.13%), with a diversified top-10 averaging under 4% each. Sector concentration is meaningful, with Pharmaceuticals (18.3%), Auto Components (17.6%), and Chemicals (11.0%) forming the top three exposures. The portfolio spans multinationals across pharma, capital goods, and specialty chemicals, consistent with the MNC theme.
The fund lags its sectoral/thematic category on SIP XIRR at every horizon, trailing the 5Y category average of 17.45% with its own 13.56%. Its strength lies in consistency and lower volatility rather than headline returns, evidenced by stable long-horizon XIRR between 12.3% and 13.56% over 3Y to 12Y. Calendar-year returns show wide dispersion, from 67.26% in 2014 to -9.24% in 2018, typical of a thematic mandate.
This fund suits investors seeking steady, lower-volatility thematic exposure to Indian multinationals with a horizon of 7 years or more, given its long-term alpha over the NIFTY 50. It is appropriate for moderate-risk investors who prioritize downside protection, as reflected in downside capture near 54-57% over long periods. It should be a satellite allocation rather than a core holding due to its thematic concentration and underperformance versus category peers.
- Consistent long-term outperformance versus NIFTY 50, with 15Y fund CAGR of 12.54% versus benchmark 9.23% and alpha of 4.45%
- Strong downside protection with downside capture of 56.28% over 12Y and low beta around 0.60
- Stable risk-adjusted returns with Calmar ratios of roughly 0.50-0.61 across all horizons
- SIP XIRR trails the category average at every horizon, including 13.56% versus 17.45% over 5Y
- Thematic concentration risk, with pharma and auto components together exceeding 35% of the portfolio
Generated on 26-10-2026, 2:15 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.71 L | 17.8% | -38.6% | 102.2% |
| 3 Years | ₹36.00 L | ₹43.13 L | 13.2% | -12.8% | 33.5% |
| 5 Years | ₹60.00 L | ₹84.15 L | 13.1% | -3.8% | 24.7% |
| 7 Years | ₹84.00 L | ₹1.34 Cr | 13.4% | 3.6% | 18.1% |
| 10 Years | ₹1.20 Cr | ₹2.43 Cr | 13.3% | 9.2% | 16.0% |
| 12 Years | ₹1.44 Cr | ₹3.09 Cr | 12.4% | 9.8% | 15.5% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 17.8% | 14.3% | 10.6% | +3.5% |
| 3 Years | 13.2% | 11.0% | 16.2% | +2.2% |
| 5 Years | 13.1% | 10.4% | 17.4% | +2.7% |
| 7 Years | 13.4% | 10.6% | 16.6% | +2.9% |
| 10 Years | 13.3% | 11.4% | 16.4% | +1.8% |
| 12 Years | 12.4% | 11.3% | 15.8% | +1.0% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 16.8% | 12.2% | -18.7% | 86.0% | 0.50 | 2.02 | 82% | — | — |
| 3 Years | 14.3% | 12.8% | -0.8% | 34.7% | 1.10 | 11.60 | 100% | — | — |
| 5 Years | 14.1% | 14.3% | 1.1% | 25.7% | 1.66 | 18.31 | 100% | — | — |
| 10 Years | 14.0% | 12.9% | 9.8% | 19.8% | 2.66 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +15.08 | 0.77 | 80.5% | 59.6% | 8.2% | -10.9% |
| 3 Years | +0.31 | 0.61 | 62.8% | 59.2% | 6.8% | 6.4% |
| 5 Years | +1.05 | 0.61 | 62.1% | 57.4% | 6.7% | 5.2% |
| 7 Years | +3.68 | 0.57 | 59.6% | 52.8% | 12.2% | 10.0% |
| 10 Years | +1.97 | 0.60 | 62.0% | 56.7% | 10.8% | 10.3% |
| 12 Years | +3.52 | 0.60 | 62.8% | 56.0% | 11.5% | 9.0% |
| 15 Years | +4.68 | 0.58 | 62.5% | 53.7% | 12.9% | 9.4% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Divi's Laboratories Ltd. | 5.82% |
| 2 | Cummins India Ltd. | 4.77% |
| 3 | Bosch Ltd. | 4.13% |
| 4 | Sona Blw Precision Forgings Ltd. | 3.90% |
| 5 | Vedanta Aluminium Metal Ltd. | 3.88% |
| 6 | Navin Fluorine International Ltd. | 3.62% |
| 7 | Sun Pharmaceutical Industries Ltd. | 3.42% |
| 8 | Aether Industries Ltd. | 3.20% |
| 9 | ABB India Ltd. | 3.19% |
| 10 | Siemens Ltd. | 2.92% |